Aclaris Therapeutics Inc - ESG Rating & Company Profile powered by AI
If you work at Aclaris Therapeutics Inc and you would like to use your Sustainability aseessment, please get in touch. Detailed ESG analysis of Aclaris Therapeutics Inc can be reached by logging in. This Disclosure rating includes seventeen UN Sustainable Development Goals including: 'Good Health & Wellbeing', 'Responsible Production & Consumption' and 'Partnerships for the Goals'.
Aclaris Therapeutics Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 3.9; made up of an environmental score of 2.0, social score of 3.2 and governance score of 6.4.
3.9
Low ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| 1004 | Xeris Pharmaceuticals Inc | 4.0 | High |
| 1004 | Xenon Pharmaceuticals Inc | 4.0 | High |
| ... | ... | ... | |
| 1089 | Aclaris Therapeutics Inc | 3.9 | Medium |
| 1089 | Allogene Therapeutics Inc | 3.9 | Medium |
| 1089 | Hua Medicine | 3.9 | Medium |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Aclaris Therapeutics Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Aclaris Therapeutics Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes Aclaris Therapeutics Inc report the average age of the workforce?
Sign up for free to unlockDoes Aclaris Therapeutics Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Aclaris Therapeutics Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes Aclaris Therapeutics Inc disclose cybersecurity risks?
Sign up for free to unlockDoes Aclaris Therapeutics Inc offer flexible work?
Sign up for free to unlockDoes Aclaris Therapeutics Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Aclaris Therapeutics Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Aclaris Therapeutics Inc conduct supply chain audits?
Sign up for free to unlockDoes Aclaris Therapeutics Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Aclaris Therapeutics Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes Aclaris Therapeutics Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes Aclaris Therapeutics Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Aclaris Therapeutics Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Aclaris Therapeutics Inc disclose water use targets?
Sign up for free to unlockDoes Aclaris Therapeutics Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid Aclaris Therapeutics Inc have a product recall in the last two years?
Sign up for free to unlockDoes Aclaris Therapeutics Inc disclose incidents of discrimination?
Sign up for free to unlockDoes Aclaris Therapeutics Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Aclaris Therapeutics Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Aclaris Therapeutics Inc disclose parental leave metrics?
Sign up for free to unlockDoes Aclaris Therapeutics Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Aclaris Therapeutics Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Aclaris Therapeutics Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes Aclaris Therapeutics Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Aclaris Therapeutics Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Aclaris Therapeutics Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Aclaris Therapeutics Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes Aclaris Therapeutics Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Aclaris Therapeutics Inc disclose its waste policy?
Sign up for free to unlockDoes Aclaris Therapeutics Inc report according to TCFD requirements?
Sign up for free to unlockDoes Aclaris Therapeutics Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Aclaris Therapeutics Inc disclose energy use targets?
Sign up for free to unlockDoes Aclaris Therapeutics Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Aclaris Therapeutics Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Aclaris Therapeutics Inc
These potential risks are based on the size, segment and geographies of the company.
Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment engages in the provision of laboratory services. The company also develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis. In addition, it develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an MK2 inhibitor treatment for pancreatic and metastatic breast cancer. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.